342 results on '"Colonno, Richard"'
Search Results
2. Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection
3. Safety and efficacy of vebicorvir in virologically suppressed patients with chronic hepatitis B virus infection
4. Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
5. Targeting a Binding Pocket within the Trimer-of-Hairpins: Small-Molecule Inhibition of Viral Fusion
6. A Small Molecule HIV-1 Inhibitor That Targets the HIV-1 Envelope and Inhibits CD4 Receptor Binding
7. Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study
8. Preclinical characterization of ABI-H2158, an HBV core inhibitor with dual mechanisms of action
9. Human Immunodeficiency Virus Type 1 Viral Background Plays a Major Role in Development of Resistance to Protease Inhibitors
10. Development of Entecavir: Superior Therapy for the Management of Chronic Hepatitis B Viral Infection
11. Identification of I50L as the Signature Atazanavir (ATV)-Resistance Mutation in Treatment-Naive HIV-1-Infected Patients Receiving ATV-Containing Regimens
12. Virus Receptors: The Achilles’ Heel of Human Rhinoviruses
13. Molecular Interactions between Human Rhinoviruses and the Adhesion Receptor ICAM-1
14. Utilization of in vitro Caco‐2 permeability and liver microsomal half‐life screens in discovering BMS‐488043, a novel HIV‐1 attachment inhibitor with improved pharmacokinetic properties
15. Long-Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis Infection
16. In vitro Synthesis of Messenger RNA by a Defective Interfering Particle of Vesicular Stomatitis Virus
17. Biochemical Studies on Capped RNA Primers Identify a Class of Oligonucleotide Inhibitors of the Influenza Virus RNA Polymerase
18. Methylation of Messenger RNA of Newcastle Disease Virus in vitro by a Virion-Associated Enzyme
19. Molecular Cloning and Complete Sequence Determination of RNA Genome of Human Rhinovirus Type 14
20. Evidence for the Direct Involvement of the Rhinovirus Canyon in Receptor Binding
21. Sequence-Specific Interaction of Tat Protein and Tat Peptides with the Transactivation-Responsive Sequence Element of Human Immunodeficiency Virus Type 1 in vitro
22. cDNA Cloning Reveals that the Major Group Rhinovirus Receptor on HeLa Cells is Intercellular Adhesion Molecule 1
23. Accumulation of Newly Synthesized mRNAs in Response to Human Fibroblast (β ) Interferon
24. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
25. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
26. Ribavirin and mycophenolic acid markedly potentiate the anti-hepatitis B virus activity of entecavir
27. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B
28. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
29. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion
30. Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature‐Mutation in Treated Chronic Hepatitis B Patients
31. Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731
32. PPI-668, A Potent New Pan-Genotypic HCV NS5A Inhibitor: Phase 1 Efficacy and Safety: 1874
33. The effects of the Roche AMPLICOR HIV-1 MONITOR ® UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons
34. Development of a highly sensitive multiplex platform assay to monitor low levels of HBV DNA and pgRNA in samples from patients with chronic hepatitis B
35. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-positive chronic hepatitis B infection in a long-term extension study
36. Antiviral activity, pharmacokinetics and safety of the second-generation hepatitis B core inhibitor ABI-H2158 in Phase 1b study of patients with HBeAg-positive chronic hepatitis B infection
37. Antiviral activity and safety of the hepatitis B core inhibitor ABI-H0731 administered with a nucleos(t)ide reverse transcriptase inhibitor in patients with HBeAg-negative chronic hepatitis B infection
38. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy#
39. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance
40. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B
41. Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B
42. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B
43. Entecavir 2-year resistance update: no resistance observed in nucleoside-naïve patients and low frequency resistance emergence in lamivudine-refractory patients: 45
44. Preclinical Pharmacokinetics of a Novel HIV-1 Attachment Inhibitor BMS-378806 and Prediction of its Human Pharmacokinetics
45. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus
46. Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase
47. Discovery of novel potent HCV NS5B polymerase non-nucleoside inhibitors bearing a fused benzofuran scaffold
48. LBP-12-Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H, a Novel Second-Generation HBV Core Inhibitor, in Healthy Volunteers
49. THU-216-Rapid turnover of HBV cccDNA in nucleoside-treated chronic hepatitis B patients during drug resistance emergence and breakthrough
50. PS-073-Preclinical profile of HBV core protein inhibitor, ABI-H, a potent inhibitor of cccDNA generation in HBV infected cells
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.